159 related articles for article (PubMed ID: 3542268)
1. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group.
DeGregorio MW; Lum BL; Holleran WM; Wilbur BJ; Sikic BI
Cancer Chemother Pharmacol; 1986; 18(3):235-8. PubMed ID: 3542268
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of carboplatin after intraperitoneal administration.
Elferink F; van der Vijgh WJ; Klein I; ten Bokkel Huinink WW; Dubbelman R; McVie JG
Cancer Chemother Pharmacol; 1988; 21(1):57-60. PubMed ID: 3277734
[TBL] [Abstract][Full Text] [Related]
3. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients.
Chambers SK; Chambers JT; Davis CA; Kohorn EI; Schwartz PE; Lorber MI; Handschumacher RE; Pizzorno G
J Clin Oncol; 1997 May; 15(5):1945-52. PubMed ID: 9164206
[TBL] [Abstract][Full Text] [Related]
5. Comparative intraperitoneal pharmacokinetics of three platinum analogues.
Lind MJ; Murphy DJ; Sharma H; Tinker N; Smith A; McAuliffe CA; Crowther D
Cancer Chemother Pharmacol; 1991; 28(4):315-7. PubMed ID: 1879050
[TBL] [Abstract][Full Text] [Related]
6. The disposition of carboplatin in ovarian cancer patients.
Gaver RC; Colombo N; Green MD; George AM; Deeb G; Morris AD; Canetta RM; Speyer JL; Farmen RH; Muggia FM
Cancer Chemother Pharmacol; 1988; 22(3):263-70. PubMed ID: 3044634
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin.
Sasaki Y; Tamura T; Eguchi K; Shinkai T; Fujiwara Y; Fukuda M; Ohe Y; Bungo M; Horichi N; Niimi S
Cancer Chemother Pharmacol; 1989; 23(4):243-6. PubMed ID: 2647312
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
Deng C; Huang R; Lian L
Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):159-62. PubMed ID: 8758790
[TBL] [Abstract][Full Text] [Related]
9. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.
Steller MA; Egorin MJ; Trimble EL; Bartlett DL; Zuhowski EG; Alexander HR; Dedrick RL
Cancer Chemother Pharmacol; 1999; 43(2):106-14. PubMed ID: 9923815
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study.
Miyagi Y; Fujiwara K; Kigawa J; Itamochi H; Nagao S; Aotani E; Terakawa N; Kohno I;
Gynecol Oncol; 2005 Dec; 99(3):591-6. PubMed ID: 16095677
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of carboplatin.
Oguri S; Sakakibara T; Mase H; Shimizu T; Ishikawa K; Kimura K; Smyth RD
J Clin Pharmacol; 1988 Mar; 28(3):208-15. PubMed ID: 3283185
[TBL] [Abstract][Full Text] [Related]
12. Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding.
Royer B; Guardiola E; Polycarpe E; Hoizey G; Delroeux D; Combe M; Chaigneau L; Samain E; Chauffert B; Heyd B; Kantelip JP; Pivot X
Anticancer Drugs; 2005 Oct; 16(9):1009-16. PubMed ID: 16162978
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.
Speyer JL; Beller U; Colombo N; Sorich J; Wernz JC; Hochster H; Green M; Porges R; Muggia FM; Canetta R
J Clin Oncol; 1990 Aug; 8(8):1335-41. PubMed ID: 2199620
[TBL] [Abstract][Full Text] [Related]
14. Phase I study and pharmacokinetics of intraperitoneal carboplatin.
McVie JG; ten Bokkel Huinink W; Dubbelman R; Franklin H; van der Vijgh W; Klein I
Cancer Treat Rev; 1985 Sep; 12 Suppl A():35-41. PubMed ID: 3910220
[TBL] [Abstract][Full Text] [Related]
15. A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Jandial DA; Brady WE; Howell SB; Lankes HA; Schilder RJ; Beumer JH; Christner SM; Strychor S; Powell MA; Hagemann AR; Moore KN; Walker JL; DiSilvestro PA; Duska LR; Fracasso PM; Dizon DS
Gynecol Oncol; 2017 May; 145(2):236-242. PubMed ID: 28341300
[TBL] [Abstract][Full Text] [Related]
16. Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin.
Newell DR; Siddik ZH; Gumbrell LA; Boxall FE; Gore ME; Smith IE; Calvert AH
Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1399-405. PubMed ID: 3315699
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.
Mulder PO; de Vries EG; Uges DR; Scaf AH; Sleijfer DT; Mulder NH
Br J Cancer; 1990 Mar; 61(3):460-4. PubMed ID: 2183874
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of carboplatin after i.v. administration.
Elferink F; van der Vijgh WJ; Klein I; Vermorken JB; Gall HE; Pinedo HM
Cancer Treat Rep; 1987 Dec; 71(12):1231-7. PubMed ID: 3319135
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients.
Colombo N; Speyer JL; Green M; Canetta R; Beller U; Wernz JC; Meyers M; Widman T; Blum RH; Piccart M
Cancer Chemother Pharmacol; 1989; 23(5):323-8. PubMed ID: 2650904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]